Sultopride

Sultopride
Clinical data
Trade namesBarnetil, Barnotil, Topral
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral, IM
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Elimination half-life3–5 hours
Identifiers
IUPAC name
  • N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.053.293
Edit this at Wikidata
Chemical and physical data
FormulaC17H26N2O4S
Molar mass354.47 g·mol−1
3D model (JSmol)
SMILES
  • O=S(=O)(c1cc(c(OC)cc1)C(=O)NCC2N(CC)CCC2)CC
InChI
  • InChI=1S/C17H26N2O4S/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20) checkY
  • Key:UNRHXEPDKXPRTM-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Sultopride (trade names Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia.[1][2][3] It was launched by Sanofi-Aventis in 1976.[1] Sultopride acts as a selective D2 and D3 receptor antagonist.[4] It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.[5]

Pharmacology

Sultopride
Site Ki Species Ref
D2 1.6 Human [6]
D3 3.8 Human [6]

References

  1. 1 2 José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. ISBN 3-527-31058-4.
  2. ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. ISBN 3-88763-075-0.
  3. ↑ European Drug Index, 4th Edition. Boca Raton: CRC Press. 1998. ISBN 3-7692-2114-1.
  4. ↑ Burstein, E. S.; Ma, J; Wong, S; Gao, Y; Pham, E; Knapp, AE; Nash, NR; Olsson, R; Davis, RE (2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–87. doi:10.1124/jpet.105.092155. PMID 16135699.
  5. ↑ Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". Eur J Pharmacol. 256 (2): 211–4. doi:10.1016/0014-2999(94)90248-8. PMID 7914168.
  6. 1 2 Burstein, E. S.; Ma, J.; Wong, S.; Gao, Y.; Pham, E.; Knapp, A. E.; Nash, N. R.; Olsson, R.; Davis, R. E.; Hacksell, U.; Weiner, D. M. (December 2005). "Intrinsic Efficacy of Antipsychotics at Human D 2 , D 3 , and D 4 Dopamine Receptors: Identification of the Clozapine Metabolite N -Desmethylclozapine as a D 2 /D 3 Partial Agonist". Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–1287. doi:10.1124/jpet.105.092155. ISSN 0022-3565.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.